Pfizer’s stock falls 4% after halting trial of obesity drug due to side effects

Pfizer's drug helped patients lose weight but also caused nausea and diarrhea.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.